Newsroom

NEWSROOM

October 4, 2021

Galderma announces exclusive agreement with Sofregen to develop the next generation of biostimulator fillers using silk-based technology

September 23, 2021 Agreement adds cutting-edge innovation to Galderma’s aesthetic injectable portfolio, the aesthetic industry’s broadest i
October 4, 2021

Galderma to present new data from leading aesthetics portfolio and launch RESTYLANE® EYELIGHT™ at AMWC 2021

September 9, 2021 RESTYLANE® EYELIGHT™ to launch as new targeted treatment solution for under-eye shadows 
October 4, 2021

Alluzience®, the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe

June 11, 2021 Data supporting the positive decision demonstrated that patients treated with Alluzience® for wrinkles had a rapid onset of e
October 4, 2021

How Galderma's Environmental, Social and corporate Governance approach guides its roadmap for sustainable growth

May 19, 2021 Cécile Dussart discusses ESG being an integral part of Galderma's business
October 4, 2021

RESTYLANE®, the original stabilized hyaluronic acid filler, celebrates 25 years of unmatched achievement

September 30, 2021 The unsurpassed NASHA™ technology, which is still used today as the benchmark for fillers, was pioneered by Galderma
March 23, 2021

Galderma continues global growth ambition with Sculptra® (injectable poly-L-lactic acid) re-launch in Europe

March 4, 2021 Updated administration protocol means Sculptra® offers the fastest reconstitution of any injectable PLLA available in Europe.
March 23, 2021

Galderma receives FDA approval for Restylane® Defyne for chin augmentation

February 4, 2021 Represents second approved indication for Restylane Defyne in U.S. 
November 19, 2020

Galderma launches Dysport® in China for treatment of glabellar lines

November 18, 2020 Dysport® is a prescription injection for temporary improvement in the look of moderate to severe glabellar lines.
November 19, 2020

Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)

November 17, 2020 Phase 2 study on the impact of dose escalation on the duration of effect, efficacy and safety of a single dose of Dysport®